

# Alberto Bardelli, Bs

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7969703/alberto-bardelli-bs-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

247 papers	44,524 citations	90 h-index	210 g-index
272 ext. papers	51,584 ext. citations	13.1 avg, IF	7.26 L-index

#	Paper	IF	Citations
247	Detection of circulating tumor DNA in early- and late-stage human malignancies. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 224ra24	17.5	2741
246	High frequency of mutations of the PIK3CA gene in human cancers. <i>Science</i> , <b>2004</b> , 304, 554	33.3	2657
245	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1386-422	10.3	1683
244	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , <b>2010</b> , 11, 753-62	21.7	1653
243	International network of cancer genome projects. <i>Nature</i> , <b>2010</b> , 464, 993-8	50.4	1613
242	Liquid biopsies: genotyping circulating tumor DNA. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 579-86	2.2	1419
241	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. <i>Nature</i> , <b>2012</b> , 483, 100-3	50.4	1417
240	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5705-12	2.2	1358
239	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> , <b>2012</b> , 486, 532-6	50.4	1327
238	Liquid biopsy: monitoring cancer-genetics in the blood. <i>Nature Reviews Clinical Oncology</i> , <b>2013</b> , 10, 472-84	19.4	1134
237	Integrating liquid biopsies into the management of cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 531-548	19.4	970
236	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. <i>Nature</i> , <b>2002</b> , 418, 934	50.4	962
235	A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. <i>Cell</i> , <b>1994</b> , 77, 261-71	56.2	907
234	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. <i>Lancet Oncology</i> , <b>2005</b> , 6, 279-86	21.7	833
233	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. <i>Cancer Research</i> , <b>2007</b> , 67, 2643-8	10.1	708
232	A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. <i>Cancer Discovery</i> , <b>2011</b> , 1, 508-23	24.4	668
231	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. <i>Cancer Research</i> , <b>2009</b> , 69, 1851-7	10.1	642

230	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1254-61	2.2	582
229	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 1812-20	27.4	580
228	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , <b>2015</b> , 21, 795-801	50.5	557
227	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. <i>Nature</i> , <b>2014</b> , 508, 118-22	50.4	550
226	A phosphatase associated with metastasis of colorectal cancer. <i>Science</i> , <b>2001</b> , 294, 1343-6	33.3	539
225	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. <i>Nature Medicine</i> , <b>2016</b> , 22, 262-9	50.5	533
224	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 738-746	21.7	533
223	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. <i>Cancer Discovery</i> , <b>2013</b> , 3, 658-73	24.4	489
222	Colorectal cancer: mutations in a signalling pathway. <i>Nature</i> , <b>2005</b> , 436, 792	50.4	452
221	Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. <i>Nature</i> , <b>1998</b> , 391, 285-8	50.4	447
220	Toward understanding and exploiting tumor heterogeneity. <i>Nature Medicine</i> , <b>2015</b> , 21, 846-53	50.5	441
219	Mutational analysis of the tyrosine phosphatome in colorectal cancers. <i>Science</i> , <b>2004</b> , 304, 1164-6	33.3	431
218	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 1308-24	9.7	424
217	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. <i>Cancer Research</i> , <b>2004</b> , 64, 8816-20	10.1	404
216	Mutational analysis of the tyrosine kinome in colorectal cancers. <i>Science</i> , <b>2003</b> , 300, 949	33.3	392
215	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1269-80	24.4	326
214	IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. <i>Human Mutation</i> , <b>2009</b> , 30, 7-11	4.7	320
213	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 10208-13	11.5	293

212	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , <b>2017</b> , 552, 116-120	50.4	290
211	Liquid Biopsies, What We Do Not Know (Yet). <i>Cancer Cell</i> , <b>2017</b> , 31, 172-179	24.3	288
210	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 2858-66	15.9	282
209	Polyclonal Secondary Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , <b>2017</b> , 7, 252-263	24.4	262
208	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 147-153	24.4	255
207	The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. <i>Acta Neuropathologica</i> , <b>2010</b> , 119, 487-94	14.3	224
206	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 989-999	12.9	213
205	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. <i>PLoS ONE</i> , <b>2009</b> , 4, e7287	3.7	209
204	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. <i>Cell Reports</i> , <b>2014</b> , 7, 86-93	10.6	207
203	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 224ra26	17.5	203
202	Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 603-11	5.4	201
201	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 36-44	24.4	200
200	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. <i>Nature Communications</i> , <b>2015</b> , 6, 7002	17.4	178
199	A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. <i>Molecular and Cellular Biology</i> , <b>1993</b> , 13, 4600-8	4.8	175
198	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2157-66	12.9	173
197	Early-onset colorectal cancer in young individuals. <i>Molecular Oncology</i> , <b>2019</b> , 13, 109-131	7.9	173
196	AKT1(E17K) in human solid tumours. <i>Oncogene</i> , <b>2008</b> , 27, 5648-50	9.2	165
195	Alterations in vascular gene expression in invasive breast carcinoma. <i>Cancer Research</i> , <b>2004</b> , 64, 7857-66	10.1	165

194	The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. <i>Molecular and Cellular Biology</i> , <b>1996</b> , 16, 2151-63	4.8	164
193	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 3089-94	11.5	163
192	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , <b>2019</b> , 25, 1415-1421	50.5	161
191	SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. <i>Nature Medicine</i> , <b>2018</b> , 24, 961-967	50.5	158
190	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , <b>2019</b> , 9, 1064-1079	24.4	154
189	Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2515-25	12.9	152
188	Adaptive mutability of colorectal cancers in response to targeted therapies. <i>Science</i> , <b>2019</b> , 366, 1473-1480	99.3	148
187	The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. <i>Nature Medicine</i> , <b>2016</b> , 22, 624-31	50.5	145
186	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4901-14	12.9	143
185	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 1259-65	7.5	141
184	Carcinogen-specific induction of genetic instability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 5770-5	11.5	140
183	Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2381-92	12.9	139
182	Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. <i>Cancer Research</i> , <b>2007</b> , 67, 3545-50	10.1	136
181	PRL-3 expression in metastatic cancers. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 5607-15	12.9	133
180	Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. <i>Oncogene</i> , <b>1999</b> , 18, 5221-31	9.2	129
179	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. <i>BMC Cancer</i> , <b>2010</b> , 10, 631	4.8	128
178	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	126
177	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1271-81	24.4	126

176	The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1263-73	1	123
175	Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). <i>British Journal of Cancer</i> , <b>2009</b> , 101, 1261-8	8.7	121
174	Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 14119-23	5.4	121
173	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 13665	17.4	121
172	PRL-3 phosphatase is implicated in ovarian cancer growth. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6835-9	12.9	119
171	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , <b>2018</b> , 67, 1995-2005	19.2	119
170	PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. <i>Cell Reports</i> , <b>2015</b> , 12, 1978-85	10.6	117
169	Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. <i>Oncogene</i> , <b>1997</b> , 15, 3103-11	9.2	116
168	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2414-2422	12.9	111
167	Tumor Evolution as a Therapeutic Target. <i>Cancer Discovery</i> , <b>2017</b> ,	24.4	108
166	How liquid biopsies can change clinical practice in oncology. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1580-1590	10.3	107
165	PIK3CA cancer mutations display gender and tissue specificity patterns. <i>Human Mutation</i> , <b>2008</b> , 29, 284-9	8.7	107
164	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , <b>2017</b> , 14, 562-576	19.4	102
163	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1108-1119	10.3	101
162	EGFR Blockade Reverts Resistance to KRAS Inhibition in Colorectal Cancer. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1129-1139	24.4	100
161	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	94
160	Acquired resistance to EGFR-targeted therapies in colorectal cancer. <i>Molecular Oncology</i> , <b>2014</b> , 8, 1084-94	9.9	94
159	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1994-1999	10.3	93

158	RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. <i>Cell Reports</i> , <b>2014</b> , 8, 1475-83.6	83.6	89
157	Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. <i>Cancer Treatment Reviews</i> , <b>2014</b> , 40, 648-55	14.4	88
156	Targeted therapies: how personal should we go?. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 9, 87-97	19.4	87
155	Different point mutations in the met oncogene elicit distinct biological properties. <i>FASEB Journal</i> , <b>2000</b> , 14, 399-406	0.9	87
154	Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1998</b> , 95, 14379-83	11.5	86
153	A point mutation in the MET oncogene abrogates metastasis without affecting transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1997</b> , 94, 13868-72	11.5	82
152	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. <i>Nature Communications</i> , <b>2015</b> , 6, 8305	17.4	80
151	TGF $\beta$ and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6429-38	12.9	80
150	Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 20864-9	11.5	79
149	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , <b>2018</b> , 34, 148-162.e7	24.3	77
148	Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. <i>Cancer Research</i> , <b>2016</b> , 76, 7181-7193	10.1	73
147	Identifying tumor origin using a gene expression-based classification map. <i>Cancer Research</i> , <b>2003</b> , 63, 4144-9	10.1	72
146	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 963-71	24.4	71
145	Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. <i>International Journal of Cancer</i> , <b>1999</b> , 82, 640-3	7.5	70
144	Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. <i>Oncogene</i> , <b>1999</b> , 18, 1139-46	9.2	69
143	High-dose vitamin C enhances cancer immunotherapy. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	65
142	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 4504-15	10.1	63
141	Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. <i>Genome Biology</i> , <b>2014</b> , 15, 449	18.3	63

140	SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 16897-902	11.5	62
139	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 324ra14	17.5	61
138	Plasma HER2 () Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3046-3053	12.9	58
137	MET mutations in cancers of unknown primary origin (CUPS). <i>Human Mutation</i> , <b>2011</b> , 32, 44-50	4.7	57
136	Mutational profile of GNAQQ209 in human tumors. <i>PLoS ONE</i> , <b>2009</b> , 4, e6833	3.7	57
135	Expression and functional regulation of myoglobin in epithelial cancers. <i>American Journal of Pathology</i> , <b>2009</b> , 175, 201-6	5.8	57
134	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. <i>Cell</i> , <b>2016</b> , 165, 317-30	56.2	57
133	Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. <i>Current Drug Targets</i> , <b>2001</b> , 2, 41-55	3	55
132	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, e175245	13.4	54
131	Exploiting DNA repair defects in colorectal cancer. <i>Molecular Oncology</i> , <b>2019</b> , 13, 681-700	7.9	53
130	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1443-8	10.3	53
129	Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. <i>Oncogene</i> , <b>1999</b> , 18, 4275-81	9.2	52
128	Exploring the links between cancer and placenta development. <i>Open Biology</i> , <b>2018</b> , 8,	7	52
127	Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. <i>Annals of Oncology</i> , <b>2019</b> , 30, 211-218	10.3	51
126	The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1518-1528	24.4	51
125	A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 29274-81	5.4	50
124	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3260-7	12.9	48
123	The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2010</b> , 29, 32	12.8	48

122	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1394-1401	10.3	47
121	Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). <i>Annals of Oncology</i> , <b>2011</b> , 22, 2424-2430	10.3	47
120	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1624-1632	12.9	47
119	CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. <i>PLoS ONE</i> , <b>2016</b> , 11, e0149099	3.7	47
118	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 119-126	10.3	46
117	Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. <i>Oncogene</i> , <b>1997</b> , 14, 705-11	9.2	46
116	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 1395-1402	5.7	45
115	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3657-3666 <sup>12.9</sup>	12.9	44
114	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 73, 41-53	14.4	44
113	Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. <i>Molecular Oncology</i> , <b>2016</b> , 10, 475-80	7.9	43
112	PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. <i>Breast Cancer Research</i> , <b>2008</b> , 10, R27	8.3	43
111	Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6531-41	12.9	42
110	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, E353-9	11.5	42
109	p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 221-5	4.6	42
108	Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. <i>Cancer Research</i> , <b>2005</b> , 65, 11227	10.1	42
107	Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. <i>Journal of Biotechnology</i> , <b>1994</b> , 37, 109-22	3.7	42
106	Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. <i>ESMO Open</i> , <b>2017</b> , 2, e000253	6	40
105	Mutational analysis of gene families in human cancer. <i>Current Opinion in Genetics and Development</i> , <b>2005</b> , 15, 5-12	4.9	40

104	Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions. <i>EMBO Molecular Medicine</i> , <b>2017</b> , 9, 293-303	12	39
103	Mutational profiling of kinases in glioblastoma. <i>BMC Cancer</i> , <b>2014</b> , 14, 718	4.8	39
102	Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. <i>PLoS ONE</i> , <b>2012</b> , 7, e36402	3.7	39
101	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1372-1384	12.9	38
100	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , <b>2018</b> , 19, 1360-1371	21.7	38
99	Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. <i>Human Mutation</i> , <b>2009</b> , 30, E451-9	4.7	37
98	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. <i>FASEB Journal</i> , <b>2015</b> , 29, 464-76	0.9	35
97	Genetic targeting of the kinase activity of the Met receptor in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 11412-7	11.5	35
96	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , <b>2020</b> , 5, e000911	6	35
95	Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. <i>Human Mutation</i> , <b>2009</b> , 30, 1167-74	4.7	34
94	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 80-83	3.8	34
93	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36 Suppl 3, S1-5	14.4	32
92	Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). <i>Biochemical and Biophysical Research Communications</i> , <b>2009</b> , 386, 593-7	3.4	32
91	Recommendations for mutational analysis of EGFR in lung carcinoma. <i>Pathologica</i> , <b>2010</b> , 102, 119-26	1.9	30
90	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1062-1067	10.3	28
89	Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. <i>Cancer Research</i> , <b>2007</b> , 67, 8468-76	10.1	28
88	Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. <i>Biochemical Journal</i> , <b>1998</b> , 336 ( Pt 1), 235-9	3.8	28
87	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4312-4322	12.9	27

86	Somatic alterations as the basis for resistance to targeted therapies. <i>Journal of Pathology</i> , <b>2014</b> , 232, 244-54	9.4	27
85	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1135-1147	10.3	27
84	Precision oncology in metastatic colorectal cancer - from biology to medicine. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 506-525	19.4	27
83	Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. <i>Targeted Oncology</i> , <b>2010</b> , 5, 19-28	5	26
82	KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. <i>PLoS ONE</i> , <b>2011</b> , 6, e29146	3.7	26
81	Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. <i>Oncotarget</i> , <b>2016</b> , 7, 58743-58758	3.3	26
80	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. <i>Nature Communications</i> , <b>2017</b> , 8, 15617	17.4	25
79	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6243-6259	12.9	25
78	Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells. <i>Cancer Research</i> , <b>2007</b> , 67, 7088-94	10.1	25
77	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , <b>2018</b> , 3, e000299	6	24
76	Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1302-1308	10.3	23
75	Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers. <i>Pathobiology</i> , <b>2018</b> , 85, 146-154	3.6	23
74	Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. <i>Oncogene</i> , <b>2018</b> , 37, 4599-4610	9.2	23
73	PRL-3: a phosphatase for metastasis?. <i>Cancer Biology and Therapy</i> , <b>2004</b> , 3, 952-3	4.6	23
72	Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1848-9	10.3	23
71	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2017</b> , 71, 43-50	7.5	22
70	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 256-262.e2	3.8	22
69	Preclinical models for precision oncology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2018</b> , 1870, 239-246	11.2	22

68	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 347-352	8.7	22
67	MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. <i>Journal of Cellular Physiology</i> , <b>1999</b> , 181, 507-14	7	22
66	Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	21
65	Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 6346-56	12.9	21
64	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3506-3506	2.2	21
63	Lemur tyrosine kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis by regulating the levels of the BCL2 family members. <i>Cancer Letters</i> , <b>2017</b> , 389, 59-69	9.9	20
62	"Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>1997</b> , 1333, M41-51	11.2	20
61	Identification of cancer genes by mutational profiling of tumor genomes. <i>FEBS Letters</i> , <b>2005</b> , 579, 1884-908	9.8	20
60	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 51, 54-62	14.4	19
59	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. <i>Genome Medicine</i> , <b>2019</b> , 11, 42	14.4	19
58	Climbing RAS, the everest of oncogenes. <i>Cancer Discovery</i> , <b>2014</b> , 4, 19-21	24.4	18
57	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 622	5.3	17
56	Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?. <i>Cellular and Molecular Life Sciences</i> , <b>2013</b> , 70, 4131-40	10.3	16
55	HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS774-TPS774	2.2	16
54	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 91-101.e3	3.8	15
53	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , <b>2020</b> , 14, 1589-1615	5.9	15
52	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. <i>Cancer Discovery</i> , <b>2021</b> , 11, 126-141	24.4	15
51	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. <i>Nature Communications</i> , <b>2018</b> , 9, 2287	17.4	14

50	Minimal residual disease in breast cancer: in blood veritas. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2505-7	12.9	14
49	BRAF V600E is a determinant of sensitivity to proteasome inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 2950-61	6.1	14
48	Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. <i>Cancer Research</i> , <b>2013</b> , 73, 1912-21	10.1	14
47	Absence of AKT1 mutations in glioblastoma. <i>PLoS ONE</i> , <b>2009</b> , 4, e5638	3.7	14
46	Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. <i>Human Mutation</i> , <b>2014</b> , 35, 208-14	4.7	13
45	Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 1742-50	1.9	13
44	Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. <i>Oncotarget</i> , <b>2015</b> , 6, 10994-1008	3.3	12
43	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , <b>2019</b> , 4,	6	12
42	Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	11
41	Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. <i>PLoS ONE</i> , <b>2010</b> , 5, e12653	3.7	11
40	CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1844-1859	24.4	11
39	Two main mutational processes operate in the absence of DNA mismatch repair. <i>DNA Repair</i> , <b>2020</b> , 89, 102827	4.3	10
38	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1923-1937	24.4	10
37	Clonally expanded EOMES Tr1-like cells in primary and metastatic tumors are associated with disease progression. <i>Nature Immunology</i> , <b>2021</b> , 22, 735-745	19.1	10
36	Medical research: Personalized test tracks cancer relapse. <i>Nature</i> , <b>2017</b> , 545, 417-418	50.4	9
35	Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1026-30	6.1	9
34	RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 930	9.8	8
33	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS2659-TPS2659	26.5	8

32	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 91, 102112	14.4	8
31	The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation. <i>Cell Reports</i> , <b>2021</b> , 35, 109252	10.6	8
30	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS3648-TPS3648	2.2	7
29	Activation of Eatenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response. <i>PLoS ONE</i> , <b>2012</b> , 7, e37526	3.7	7
28	Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2017</b> , 7,	5.4	6
27	Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours. <i>Neuropathology and Applied Neurobiology</i> , <b>2019</b> , 45, 655-670	5.2	6
26	Kinase mutations in cancer: chinks in the enemy's armour?. <i>Current Opinion in Oncology</i> , <b>2006</b> , 18, 69-76	4.2	6
25	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS4124-TPS4124	2.2	6
24	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
23	Scatter factor receptors are key players in a unique multistep program leading to invasive growth. <i>Novartis Foundation Symposium</i> , <b>1997</b> , 212, 133-44; discussion 144-7		6
22	Broccoli, PTEN deletion and prostate cancer: where is the link?. <i>Molecular Cancer</i> , <b>2010</b> , 9, 308	42.1	5
21	Does early metastatic seeding occur in colorectal cancer?. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 651-653	24.2	4
20	Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells. <i>Human Mutation</i> , <b>2013</b> , 34, 330-7	4.7	4
19	Inactivation of DNA repair-prospects for boosting cancer immune surveillance. <i>Genome Medicine</i> , <b>2018</b> , 10, 91	14.4	4
18	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. <i>European Radiology</i> , <b>2020</b> , 30, 4496-4503	8	3
17	Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients' avatars.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2626-2626	2.2	3
16	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3632-TPS3632	2.2	3
15	EGFR Amplification in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 1561-1569	9.7	3

14	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , 40, e292-e308	7.1	2
13	Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2794-6	12.9	2
12	Understanding how kinase-targeted therapies work. <i>Cell Cycle</i> , <b>2008</b> , 7, 1560-3	4.7	2
11	Clonal evolution and - coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. <i>ESMO Open</i> , <b>2016</b> , 1, e000079	6	2
10	Reply to E. Hawkes et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e532-e533	2.2	1
9	Evolving neoantigen profiles in colorectal cancers with DNA repair defects		1
8	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. <i>Seminars in Cancer Biology</i> , <b>2021</b> ,	12.7	1
7	Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1886-1895	24.4	1
6	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 825-837	12.5	1
5	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	1
4	Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
3	Liquid biopsies for residual disease and recurrence.. <i>Med</i> , <b>2021</b> , 2, 1292-1313	31.7	1
2	Tracking the genomic evolution of breast cancer metastasis. <i>Breast Cancer Research</i> , <b>2010</b> , 12, 302	8.3	
1	Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. <i>Current Opinion in Molecular Therapeutics</i> , <b>2010</b> , 12, 703-11		